AssetMark Inc
CSTL icon

AssetMark Inc’s Castle Biosciences CSTL Stock Holding History

AssetMark Inc’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
6,710
+931
+16% +$20.7K ﹤0.01% 1504
2026
Q1 		$142K Buy
5,779
+492
+9% +$16.1K ﹤0.01% 1429
2025
Q4 		$206K Sell
5,287
-418
-7% -$13.5K ﹤0.01% 1302
2025
Q3 		$130K Buy
5,705
+1,158
+25% +$23.5K ﹤0.01% 1365
2025
Q2 		$92.8K Buy
4,547
+567
+14% +$10.5K ﹤0.01% 1389
2025
Q1 		$79.7K Sell
3,980
-432
-10% -$10.7K ﹤0.01% 1333
2024
Q4 		$118K Sell
4,412
-800
-15% -$24.4K ﹤0.01% 1209
2024
Q3 		$149K Buy
5,212
+748
+17% +$19K ﹤0.01% 1080
2024
Q2 		$97.2K Buy
4,464
+506
+13% +$11.3K ﹤0.01% 1113
2024
Q1 		$87.7K Sell
3,958
-778
-16% -$16.9K ﹤0.01% 1066
2023
Q4 		$102K Buy
4,736
+832
+21% +$14.6K ﹤0.01% 1031
2023
Q3 		$65.9K Buy
3,904
+994
+34% +$17.4K ﹤0.01% 1043
2023
Q2 		$39.9K Buy
2,910
+672
+30% +$13.6K ﹤0.01% 1130
2023
Q1 		$50.8K Buy
2,238
+738
+49% +$18K ﹤0.01% 1031
2022
Q4 		$35.3K Buy
1,500
+1,025
+216% +$23.8K ﹤0.01% 1113
2022
Q3 		$12K Hold
475
– – ﹤0.01% 1205
2022
Q2 		$10K Buy
475
+375
+375% +$8.71K ﹤0.01% 1217
2022
Q1 		$4K Hold
100
– – ﹤0.01% 1309
2021
Q4 		$4K Sell
100
-225
-69% -$11.8K ﹤0.01% 1263
2021
Q3 		$22K Hold
325
– – ﹤0.01% 923
2021
Q2 		$24K Hold
325
– – ﹤0.01% 871
2021
Q1 		$22K Hold
325
– – ﹤0.01% 852
2020
Q4 		$22K Buy
+325
New +$17.6K ﹤0.01% 834

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's CSTL Position: Q2 2026 in Review

AssetMark Inc increased its Castle Biosciences (CSTL) stake by 16% in Q2 2026, buying an estimated $20.7K and bringing the position to 6,710 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1504.

AssetMark Inc first reported a position in CSTL in Q4 2020 and has held it in 23 quarters since. The position peaked at $206K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • AssetMark Inc held 6,710 shares of Castle Biosciences worth $160K as of Q2 2026.
  • AssetMark Inc bought 931 Castle Biosciences shares in Q2 2026, an estimated $20.7K.
  • Castle Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1504 holding.
  • AssetMark Inc first reported a position in Castle Biosciences in Q4 2020 and has held it in 23 quarters since.
  • AssetMark Inc's Castle Biosciences position peaked at $206K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.